Inhibikase Therapeutics Inc. (IKT) News
Filter IKT News Items
IKT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest IKT News From Around the Web
Below are the latest news stories about INHIBIKASE THERAPEUTICS INC that investors may wish to consider to help them evaluate IKT as an investment opportunity.
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity-- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension -- --201 Trial Results to be reported in 4Q2024 -- BOSTON and ATLANTA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of |
Inhibikase Therapeutics Secures Funding and Strengthens LeadershipInhibikase Therapeutics ( (IKT) ) has shared an update. Inhibikase Therapeutics, Inc. has secured approximately $110 million through a private placement, boosting its potential financing to $275 million upon full exercise of warrants. This funding supports the Phase 2b trial of IkT-001Pro, aimed at treating Pulmonary Arterial Hypertension, signifying a pivotal step in the company’s mission to develop disease-modifying therapies. The closing also coincides with strategic board appointments, enhan |
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics IncOn October 21, 2024, Perceptive Advisors LLC, a prominent investment firm, initiated a new position in Inhibikase Therapeutics Inc (NASDAQ:IKT), purchasing 8,194 shares at a price of $2.22 each. This transaction marks a significant new investment by the firm into the biotechnology sector, specifically targeting a company focused on innovative treatments for Parkinson's disease and related disorders. Perceptive Advisors LLC, based in New York, is known for its strategic investments primarily in the healthcare and financial services sectors. |
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 -- BOSTON and ATLANTA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Cardiopulmonary and Neurodegenerative disease through Abe |
Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics IncOn October 9, 2024, Fairmount Funds Management LLC (Trades, Portfolio) made a significant new investment in the biotechnology sector by purchasing 6,620,311 shares of Inhibikase Therapeutics Inc (NASDAQ:IKT). This transaction, executed at a price of $1.26 per share, marks a new holding for the firm and reflects a substantial commitment, as these shares now constitute 0.93% of their portfolio and 9.90% of the company's outstanding shares. |
Inhibikase Therapeutics Secures $110M for Drug DevelopmentInhibikase Therapeutics ( (IKT) ) has shared an update. Inhibikase Therapeutics, Inc. has entered into an agreement for a private placement transaction valued at approximately $110 million with institutional and accredited investors. The company plans to issue over 58 million shares of common stock, as well as pre-funded and Series Warrants, which are immediately exercisable at nominal prices. This strategic financial move is expected to bolster Inhibikase’s pursuit of advancing its lead drug ca |
Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics SharesOn October 9, 2024, Steven Cohen (Trades, Portfolio), through Point72 Asset Management, marked a significant transaction by acquiring 625,000 shares of Inhibikase Therapeutics Inc (NASDAQ:IKT). The total shares now held in IKT account for 8.40% of the company's outstanding shares, showcasing a substantial commitment to this biotechnology entity. |
Inhibikase Therapeutics Unveils PAH and Parkinson’s Drug PipelineInhibikase Therapeutics ( (IKT) ) has provided an announcement. Inhibikase Therapeutics, Inc. released a new presentation on their website detailing the development of disease-modifying therapeutics for Pulmonary Arterial Hypertension (PAH). The company’s multi-therapeutic pipeline includes IkT-001Pro, a prodrug of imatinib mesylate with a significant market potential, and Risvodetinib for untreated Parkinson’s disease, with Phase 2 results expected soon. The presentation underscores the high un |
Inhibikase Therapeutics Prices $110 Million Private Placement; Shares JumpInhibikase Therapeutics Prices $110 Million Private Placement; Shares Jump |
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension-- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or the “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of cardiopulmonary and neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the pricing of an approxi |